title: Increased plasma soluble tumor necrosis factor receptor-1 and myeloperoxidase activity in patients with obstructive sleep apnea syndrome.
abstract: OBJECTIVE
  Obstructive sleep apnea (OSA) is characterized by recurrent respiratory disorders associated with increased cardiovascular morbidity and mortality. The increment of systemic inflammation in OSA has been considered as the major pathogenic mechanism leading to cardiovascular diseases. There is limited and conflicting information in the literature investigating myeloperoxidase (MPO) activity and soluble tumor necrosis factor receptor-1 (sTNF-R1) levels in OSA patients. The aim of our study is to assess the clinical utility of plasma MPO activity and sTNF-R1 levels as risk markers for systemic inflammation and development of cardiovascular diseases in OSA patients.
  
  
  METHODS
  59 OSA patients diagnosed with polysomnograhpy for Apnea-Hypopnea index (AHI), and 26 healthy volunteers enrolled into the study. Plasma MPO activity was measured using a spectrophotometric method. An enzyme-linked immunosorbent assay (ELISA) method was used to detect plasma sTNF-R1 levels.
  
  
  RESULTS
  Plasma MPO activity and sTNF-R1 levels were significantly higher (43.2 ± 21.65 vs. 30.44 ± 8.05 p = .0046; 2.379 ± 1.2 vs. 1.086 ± 0.86 p < .0001, respectively) in the total OSA patients compared to the control group. There was a significant weak correlation between MPO activity and disease severity indicator AHI (p = .03 r = .27).
  
  
  CONCLUSIONS
  Elevated plasma MPO activity and sTNF-R1 levels in the OSA patients indicate increased systemic inflammation and oxidative stress which might contribute to the higher incidence of cardiovascular diseases. Therefore, we recommend measurement of plasma MPO activity and sTNF-R1 levels in the OSA patients as potential risk predictors for cardiovascular diseases.
authors.affiliation: 1Medical Faculty, Department of Medical Biochemistry, Akdeniz University , 07070, Antalya , Turkey.
authors.forename: Ferhat
authors.initials: F
authors.lastname: Hanikoglu
authors.forename: Nergiz
authors.initials: N
authors.lastname: Huseyinoglu
authors.forename: Serkan
authors.initials: S
authors.lastname: Ozben
authors.forename: Aysegul
authors.initials: A
authors.lastname: Cort
authors.forename: Sebahat
authors.initials: S
authors.lastname: Ozdem
authors.forename: Tomris
authors.initials: T
authors.lastname: Ozben
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000097:blood* / Q000209:etiology; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood*; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000502:physiology*; D009195:Peroxidase / Q000097:blood / Q000378:metabolism*; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000097:blood*; D012720:Severity of Illness Index; D020181:Sleep Apnea, Obstructive / Q000097:blood* / Q000150:complications
chemical_list: D015415:Biomarkers; D047888:Receptors, Tumor Necrosis Factor, Type I; D009195:Peroxidase
keywords: Obstructive sleep apnea; cardiovascular diseases; myeloperoxidase; soluble tumor necrosis factor receptor-1